The therapeutic efficacies of cefadroxil and cephalexin were compared in a Streptococcus pyogenes-induced lung infection in rats. Although MICs, rates of in vitro killing in rat serum, and antibiotic serum levels after oral administration were similar for both drugs, cefadroxil was about eight times more 
The in vivo evaluation of new anti-infective agents is generally carried out in systemically infected mice. These infections are characterized by an early and overwheltning septicemia which bears little resemblance to the type of localized infections usually caused by these organisms in humans. Most animals infected in this manner are moribund within 12 h and dead 24 h postinfection. Since the interval between infection and treatment must, of necessity, be very short, the results obtained are more representative of prophylactic than therapeutic efficacy. Additionally,, in these models it is not possible to determine the influence of changes in the tissue microenvironment (pH, temperature, electrolyte concentration, presence of pus and necrotic tissue debris, etc.) brought about by inflammatory processes at the site of infection. These factors may significantly influence drug action by affecting antimicrobial activity and pharmacokinetic properties. It is quite possible, therefore, that antibiotics which have similar in vitro activities and comparable 50% protective dose (PD50) values in mouse systemic infections may vary in their therapeutic efficacy in localized infections. The advantages of discriminative (localized) models over screening models of chemotherapy have been reviewed by Zak and Sande (13) .
The present report describes the relative antimicrobial effectiveness of cefadroxil and cephalexin in an experimental Streptococcus pyogenes lung iinfection in rats. The development of this test model was based on the work of Nungester and Jourdonais (9) and Wood (12 
MATERIALS AND METHODS
Test organism and antibiotics. S. pyogenes A9604L was maintained as a stock culture in skim milk at -20°C. In vitro and in vivo experiments were carried out with a brain heart infusion broth (BHIB) culture which had been incubated at 36°C on a Gyrotory shaker (model G-2; New Brunswick Scientific Co., Inc., Edison, N.J.) for 4 h. Cefadroxil monohydrate (Bristol-Myers Co., Industrial Division, Syracuse, N.Y.) and cephalexin monohydrate (Eli Lilly & Co., Indianapolis, Ind.) were used throughout these studies.
Activities of cefadroxil and cephalexin in vitro. The MICs of cefadroxil and cephalexin for S. pyogenes A9604L were determined in BHIB, Mueller-Hinton broth, and pooled normal rat serum. The rat serum was heated at 56°C for 30 min and adjusted to pH 7.0 with 1 N HCI before inoculation. Serum was maintained at a pH of 7.0 to 7.4 by capping the tubes with a rubber stopper. Twofold serial dilutions of the drugs were carried out in broth or serum (final volume, 0.5 ml). A streptococcal cell suspension in the appropriate medium (0.5 ml) was added to the drug solutions to give a final concentration of approximately 5 x 105 CFU/ml. MICs were determined after incubation for 18 h at 360C.
The influence of various drug concentrations, above and below the MIC, on the rate of killing of S. pyogenes was determined in pooled rat serum; A 0.1-ml portion of a solution of cefadroxil or cephalexin at a given concentration In the first series of experiments these drugs were administered by gavage 24 h postinfection, and in the second group of experiments they were given three times, at 24, 27, and 30 h postchallenge. (11) .
RESULTS
Activity of cefadroxil and cephalexin in vitro. The activity of cefadroxil and cephalexin against S. pyogenes A9604L was examined in BHIB, Mueller-Hinton broth, and rat serum (Table 1) . Cefadroxil was more active than cephalexin by twofold in Mueller-Hinton broth and rat serum and by fourfold in BHIB. The MICs of cefadroxil and cephalexin in rat serum, 0.78 and 1.56 ,ug/ml, respectively, corresponded to the bactericidal concentrations as determined by the kill curve procedure in serum ( Fig. 1 and 2 ). Increasing the concentration to 12.5 ,ug/ml did not influence the rate of killing over that observed at the MIC.
Experimental streptococcal pneumonia of rats. The influence of the number of organisms on percentage of mortality and survival time is presented in Table 2 . During the first 24 h postinfection there were no deaths, even with the highest challenge, 2 x 105 CFU. At 48 h, 20% of the animals infected with this challenge died. This increased to 73% on day 3 postinfection, and by day 5, mortality was 100%. When 2 x 104 organisms were instilled, the first deaths occurred on day 3, and all rats died by day 7. With a challenge of 2 x 13 CFU, 53% were dead by day 14 of the experiment. The challenge selected for our studies was 1 x 105 to 5 x 105 organisms.
Therapeutic efficacy of cefadroxil and cephalexin. The PD50 of cefadroxil (2.8 mg/kg) was seven times lower than that of cephalexin (21 mg/kg) after a single oral treatment 24 h postinfection (Table 3) . When treatnment was administered 24, 27, and 30 h postinfection, cefadroxil (PD50 = 0.7 mg/kg) was 11-fold more effective than cephalexin (PD50 = 8.0 mg/kg) ( Table 4 ). Survival of S. pyogenes in lungs of rats after single or multiple treatment is shown in Table 5 . In close agreement with the PD50 differences, the concentration of cefadroxil required to reduce viable cell counts below the detection limit (10 per lung) was eightfold lower than that of cephalexin.
Concentrations of cefadroxil and cephalexin in serum and lung tissue of infected rats. Since the differences in therapeutic efficacy could not be correlated with differences in activity in vitro, we examined antibiotic levels in serum and lung tissue after oral administration of a dose of 25 mg of cefadroxil or cephalexin per kg. In terms of the AUC as well as the half-life (tj/2) in serum, these drugs were comparable (Table 6 ). In contrast, the area under the lung tissue concentration versus time curve for cefadroxil was 42% larger (P < 0.01) than that of cephalexin (Table 6 ). In addition, the tj,2 of cefadroxil (2.3 h) in pulmonary tissue was 1 h longer than that of cephalexin (1.3 h).
DISCUSSION
Cefadroxil afforded significantly better protection than cephalexin in the pneumonia model described in the present VOL. 30, 1986 After an oral dose of 25 mg/kg to infected animals, concentrations of cefadroxil and cephalexin in serum did not differ significantly throughout the observation period. In contrast, cefadroxil attained higher concentrations in lung tissue than cephalexin, and the area under the lung tissue concentration curve of cefadroxil was significantly larger than that of cephalexin. Also, the half-life of cefadroxil was 1 h longer than that of cephalexin. Consequently, at this dose, infecting organisms in bronchial tissues and fluids were exposed for longer time intervals to effective concentrations of cefadroxil than to cephalexin. Since the binding of cefadroxil and cephalexin to rat serum proteins has been shown to be similar (8) , it can be assumed that the amount of free drug available to penetrate into infected tissues was comparable. As Pennington (10) has pointed out, passage of free drug from blood into the lungs as well as its activity in infected pulmonary tissues may be influenced by the presence of tissue breakdown products, bacterial debris, purulent material, and increased amounts of respiratory tract mucus. It is possible, therefore, that these factors may have a greater adverse effect on the antistreptococcal activity and penetration of cephalexin than cefadroxil. Also, it appears that inactivation of cephalexin may be taking place at the site of infection, resulting in a shorter half-life for this drug. These effects may account for the larger AUC of cefadroxil in homogenates of infected lung tissue.
Assuming the concentration of both drugs in pulmonary tissue is linearly proportional to dose, it is interesting that all rats treated with 12.5 mg of cefadroxil per kg survived (Table  3) although this dose probably gave lung tissue levels comparable to its MBC (0.78 ,ug/ml) for only 2 h (Table 6 ). In order to assure a similar survival rate with cephalexin, it was necessary to administer 100 mg/kg. At this dose it can be estimated that the MBC of cephalexin (1.56 ,ug/ml) was maintained in lung tissue for at least 5 h. Therefore, higher lung tissue concentrations alone do not seem to account for the greater therapeutic efficacy of cefadroxil. It may well be that at subinhibitory concentrations cefadroxil is more effective than cephalexin in eliminating the causative organisms from the site of infection in the lungs. In this connection, it has been shown that subinhibitory concentrations of antiinfective agents can influence the sensitivity of microorganisms to phagocytosis (6) as well as prevent their adherence to the surface structures of host cells (1, 2) . Alternatively, it is also possible that the antistreptococcal activity of cefadroxil may continue for a longer interval, after its disappearance from infected tissues, than is the case with cephalexin. This persistent or postantibiotic effect has been described by Bundtzen et al. (4) .
In summary, the present report emphasizes the important role that localized infections in experimental animals can play in differentiating the therapeutic potential of antiinfective agents, in this case cefadroxil and cephalexin, which by conventional systemic infections in mice appear to be equally efficacious. The challenge will be to devise animal models that allow extrapolation to human infections.
